1-hydroxy-4-phenylpentan-2-one | 1067187-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-hydroxy-4-phenylpentan-2-one
• 英文别名: hydroxy-4-phenylpentan-2-one
• CAS: 1067187-85-2
• 化学式: C₁₁H₁₄O₂
• 分子量: 178.231
• InChiKey: AGJNVJRYBZIGEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-hydroxy-4-phenylpentan-2-one 、 7-三氟甲基靛红 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 以17.6%的产率得到3-hydroxy-2-(2-phenylpropyl)-8-(trifluoromethyl)quinoline-4-carboxylic acid
  参考文献：
  名称：

  Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury

  摘要：

  Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

  DOI：

  10.1021/jm9013696
• 作为产物：
  描述：

  4-戊烯-2-基苯 在 4,5-二氮芴-9-酮 、 双氧水 、 palladium diacetate 、 三氟乙酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.0h， 以68%的产率得到1-hydroxy-4-phenylpentan-2-one
  参考文献：
  名称：

  Dual Role of H₂O₂ in Palladium-Catalyzed Dioxygenation of Terminal Alkenes

  摘要：

  A pallaclium-catalyzed, environmentally friendly dioxygenation reaction of simple alkenes has been developed that enabled rapid assembly of valuable a-hydroxy ketones with high atom economy. Notably, control experiments and 180 isotope-labeling experiments established that H2O2 played a dominant dual role in this transformation.

  DOI：

  10.1021/acs.orglett.7b01228

文献信息

• Methods and Compositions for Selectin Inhibition
  申请人：Kaila Neelu

  公开号：US20080255192A1

  公开（公告）日：2008-10-16

  The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

  本教学涉及到式I的新化合物： 其中组成变量如本文所定义。本教学的化合物可以作为被称为选择素的哺乳动物粘附蛋白的拮抗剂。提供了治疗或预防选择素介导的疾病的方法，包括以治疗有效剂量给予这些化合物。
• [EN] PROCESS FOR PRODUCING ALPHA-HYDROXYKETONE COMPOUND<br/>[FR] PROCÉDÉ DE PRODUCTION DE COMPOSÉ ALPHA-HYDROXYCÉTONE
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2013157651A1

  公开（公告）日：2013-10-24

  An object of the present invention is to provide a new process for producing an α-hydroxyketone compound. The present invention relates to a process for producing an α-hydroxyketone compound comprising mixing at least hydrophobic solvent selected from the group consisting of an aromatic hydrocarbon solvent, an aliphatic hydrocarbon solvent, a halo-hydrocarbon solvent, and an ether solvent incompatible with water, a compound defined by the formula (1) wherein, R1 and R2 are each independently a hydrogen atom, an optionally substituted alkyl group; R3 is an optionally substituted alkyl group or an aryl group; and X- is an anion, a basic compound, formalin, and an aldehyde compound with 2 to 30 carbon atoms.

  本发明的一个目的是提供一种生产α-羟基酮化合物的新工艺。本发明涉及一种生产α-羟基酮化合物的工艺，包括将至少选择自芳香烃溶剂、脂肪烃溶剂、卤代烃溶剂和与水不相容的醚溶剂的疏水性溶剂，与化学式（1）所定义的化合物混合，其中，R1和R2各自独立地是氢原子、可选择取代的烷基团；R3是可选择取代的烷基团或芳基团；X-是阴离子、碱性化合物、甲醛和碳原子数为2到30的醛化合物。
• QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION
  申请人：Wyeth

  公开号：EP2134692A2

  公开（公告）日：2009-12-23
• [EN] METHODS AND COMPOSITIONS FOR SELECTIN INHIBITION<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR L'INHIBITION DE LA SÉLECTINE
  申请人：WYETH CORP

  公开号：WO2008121817A2

  公开（公告）日：2008-10-09

  [EN] The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selectins. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.
  [FR] La présente invention concerne de nouveaux composés de la formule I: LA FORMULE CHIMIQUE DOIT ETRE INSEREE ICI TELLE QU'ELLE APPARAiT SUR LE RESUME DU FORMAT PAPIER, où les variables sont telles que définies ici. Les composés de la présente invention peuvent agir comme antagonistes des protéines mammaliennes d'adhésion connus comme sélectines. Des procédés de traitement ou de prévention de désordres à médiation par les sélectines sont décrits, lesquels comprennent l'administration de ces composés en une quantité thérapeutiquement efficace.
• Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury
  作者：Adrian Huang、Alessandro Moretto、Kristin Janz、Michael Lowe、Patricia W. Bedard、Steve Tam、Li Di、Valerie Clerin、Natalia Sushkova、Boris Tchernychev、Desiree H. H. Tsao、James C. Keith、Gray D. Shaw、Robert G. Schaub、Qin Wang、Neelu Kaila

  DOI：10.1021/jm9013696

  日期：2010.8.26

  Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.